INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341394, 'Almotriptan', 'Rizatriptan', 'Major', 'Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic reactions, including coronary artery vasospasm, peripheral vascular ischemia and colonic ischemia, due to additive pharmacologic effects.', 'DDInter', 1767317475, 'The concomitant use of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications, or use within 24 hours of each other, is considered contraindicated.', 'Synergism', 'The concomitant use of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications, or use within 24 hours of each other, is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341395, 'Almotriptan', 'Rufinamide', 'Moderate', 'Rufinamide may modestly or moderately decrease the plasma concentrations and therapeutic effects of drugs that are CYP450 3A4 substrates. The mechanism is enhanced metabolism by CYP450 3A4 enzyme induction.', 'DDInter', 1767317475, 'During concomitant treatment with rufinamide and drugs that are CYP450 3A4 substrates, it is recommended that patients should be monitored for 2 weeks when rufinamide is added to or withdrawn from therapy, or after increases of the dose. Dose adjustments of the coadministered drug may be required if an interaction is suspected.', 'Metabolism', 'During concomitant treatment with rufinamide and drugs that are CYP450 3A4 substrates, it is recommended that patients should be monitored for 2 weeks when rufinamide is added to or withdrawn from therapy, or after increases of the dose.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341396, 'Almotriptan', 'Saquinavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of almotriptan, which is partially metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. The possibility of prolonged and/or increased pharmacologic effects of almotriptan, including serious adverse effects such as vasospastic reactions, should be considered during concomitant therapy. Patients should be advised to notify their physician if they experience nausea; pain or tightness in the chest, neck, or jaw; irregular heartbeat; abnormal breathing; seizures; tremor; and/or tingling or numbness.', 'Metabolism', 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341397, 'Almotriptan', 'Selegiline', 'Moderate', 'Coadministration of selegiline with 5-HT1 receptor agonists may be associated with a theoretical risk of serotonin syndrome. The proposed mechanism involves an additive pharmacodynamic effect resulting from inhibition of serotonin metabolism and stimulation of 5-HT1A receptors.', 'DDInter', 1767317475, 'Caution is advisable when 5-HT1 receptor agonists are used with selegiline, particularly at dosages higher than that recommended for the treatment of Parkinson''s disease. Patients should be monitored for symptoms of the serotonin syndrome, which may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Metabolism, Synergism', 'Caution is advisable when 5-HT1 receptor agonists are used with selegiline, particularly at dosages higher than that recommended for the treatment of Parkinson''s disease.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341398, 'Almotriptan', 'Sertraline', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 1767317475, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341399, 'Almotriptan', 'Sibutramine', 'Major', 'Concomitant use of sibutramine with other serotonin reuptake inhibitors or other agents that possess or enhance serotonergic activity such as monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, phenylpiperidine opioids, bupropion, dextromethorphan, linezolid, lithium, St. John''s wort, tramadol, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', 'DDInter', 1767317475, 'In general, the concomitant use of sibutramine with other agents that affect the serotonergic neurotransmitter system should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when initiating or increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is recommended following use of fluoxetine and 3 weeks following use of vortioxetine before administering another serotonergic agent such as sibutramine. At least 14 days should elapse between discontinuation of other serotonergic agents and initiation of treatment with sibutramine. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'In general, the concomitant use of sibutramine with other agents that affect the serotonergic neurotransmitter system should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341400, 'Almotriptan', 'Sirolimus', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 1767317475, 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341401, 'Almotriptan', 'St. John''s Wort', 'Moderate', 'Concomitant use of 5-HT1 receptor agonists and St. John''s wort may potentiate the risk of serotonergic effects, including serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A receptors.', 'DDInter', 1767317475, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Some authorities recommend that St. John''s wort should be stopped during treatment with 5-HT1 agonists.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341402, 'Almotriptan', 'Sumatriptan', 'Major', 'Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic reactions, including coronary artery vasospasm, peripheral vascular ischemia and colonic ischemia, due to additive pharmacologic effects.', 'DDInter', 1767317475, 'The concomitant use of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications, or use within 24 hours of each other, is considered contraindicated.', 'Synergism', 'The concomitant use of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications, or use within 24 hours of each other, is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341403, 'Almotriptan', 'Tacrolimus', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 1767317475, 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341404, 'Almotriptan', 'Tapentadol', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 1767317475, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341405, 'Almotriptan', 'Telaprevir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of almotriptan, which is partially metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. The possibility of prolonged and/or increased pharmacologic effects of almotriptan, including serious adverse effects such as vasospastic reactions, should be considered during concomitant therapy. Patients should be advised to notify their physician if they experience nausea; pain or tightness in the chest, neck, or jaw; irregular heartbeat; abnormal breathing; seizures; tremor; and/or tingling or numbness.', 'Metabolism', 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341406, 'Almotriptan', 'Telithromycin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of almotriptan, which is partially metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. The possibility of prolonged and/or increased pharmacologic effects of almotriptan, including serious adverse effects such as vasospastic reactions, should be considered during concomitant therapy. Patients should be advised to notify their physician if they experience nausea; pain or tightness in the chest, neck, or jaw; irregular heartbeat; abnormal breathing; seizures; tremor; and/or tingling or numbness.', 'Metabolism', 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341407, 'Almotriptan', 'Temsirolimus', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 1767317475, 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341408, 'Almotriptan', 'Tizanidine', 'Moderate', 'The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects. In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation. Tizanidine itself is a central alpha-2 adrenergic agonist. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.', 'DDInter', 1767317475, 'Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position. Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.', 'Synergism', 'Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341409, 'Almotriptan', 'Tranylcypromine', 'Major', 'The 5-HT1 receptor agonists used to treat migraine headaches exhibit modest 5-HT1A activity. Theoretically, MAOIs may potentiate the serotonergic activity of 5-HT1 receptor agonists and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. The mechanism is an additive pharmacodynamic effect resulting from MAOI inhibition of serotonin metabolism. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 1767317475, 'Concomitant use of 5-HT1 receptor agonists with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) should generally be avoided. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with 5-HT1 receptor agonists. Otherwise, patients should be closely monitored for adverse effects related to excessive serotonergic activity.', 'Synergism', 'Concomitant use of 5-HT1 receptor agonists with MAOIs or other agents that possess MAOI activity (e.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341410, 'Almotriptan', 'Trazodone', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 1767317475, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341411, 'Almotriptan', 'Troleandomycin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of almotriptan, which is partially metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. The possibility of prolonged and/or increased pharmacologic effects of almotriptan, including serious adverse effects such as vasospastic reactions, should be considered during concomitant therapy. Patients should be advised to notify their physician if they experience nausea; pain or tightness in the chest, neck, or jaw; irregular heartbeat; abnormal breathing; seizures; tremor; and/or tingling or numbness.', 'Metabolism', 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341412, 'Almotriptan', 'Tucatinib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of almotriptan, which is partially metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. The possibility of prolonged and/or increased pharmacologic effects of almotriptan, including serious adverse effects such as vasospastic reactions, should be considered during concomitant therapy. Patients should be advised to notify their physician if they experience nausea; pain or tightness in the chest, neck, or jaw; irregular heartbeat; abnormal breathing; seizures; tremor; and/or tingling or numbness.', 'Metabolism', 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341413, 'Almotriptan', 'Venlafaxine', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 1767317475, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341414, 'Almotriptan', 'Verapamil', 'Minor', 'According to the product labeling, coadministration of almotriptan (12.5 mg single oral dose) with verapamil (120 mg sustained-release tablets twice a day for 7 days) in healthy volunteers resulted in a 24% increase in almotriptan peak plasma concentration (Cmax) and a 20% increase in systemic exposure (AUC). The proposed mechanism is verapamil inhibition of almotriptan metabolism via CYP450 3A4.', 'DDInter', 1767317475, '-', 'Metabolism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341415, 'Almotriptan', 'Vilazodone', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 1767317475, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341416, 'Almotriptan', 'Voriconazole', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of almotriptan, which is partially metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. The possibility of prolonged and/or increased pharmacologic effects of almotriptan, including serious adverse effects such as vasospastic reactions, should be considered during concomitant therapy. Patients should be advised to notify their physician if they experience nausea; pain or tightness in the chest, neck, or jaw; irregular heartbeat; abnormal breathing; seizures; tremor; and/or tingling or numbness.', 'Metabolism', 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341417, 'Almotriptan', 'Vortioxetine', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 1767317475, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341418, 'Almotriptan', 'Zolmitriptan', 'Major', 'Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic reactions, including coronary artery vasospasm, peripheral vascular ischemia and colonic ischemia, due to additive pharmacologic effects.', 'DDInter', 1767317475, 'The concomitant use of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications, or use within 24 hours of each other, is considered contraindicated.', 'Synergism', 'The concomitant use of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications, or use within 24 hours of each other, is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341419, 'Alogliptin', 'Acetohexamide', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341420, 'Alogliptin', 'Aloe Vera Leaf', 'Moderate', 'Concomitant use of oral products containing aloe vera gel may potentiate the hypoglycemic effect of insulin and other antidiabetic agents.', 'DDInter', 1767317475, 'Until more data are available, caution is advised when aloe vera is administered orally to patients receiving insulin or other antidiabetic agents due to the potential for increased risk of hypoglycemia. Patients should be monitored for changes in diabetic medication requirements.', 'Synergism', 'Until more data are available, caution is advised when aloe vera is administered orally to patients receiving insulin or other antidiabetic agents due to the potential for increased risk of hypoglycemia.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341421, 'Alpelisib', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341422, 'Amcinonide', 'Alogliptin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341423, 'Amprenavir', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341424, 'Alogliptin', 'Aripiprazole', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341425, 'Alogliptin', 'Asenapine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341426, 'Alogliptin', 'Asparaginase Erwinia chrysanthemi', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341427, 'Alogliptin', 'Asparaginase Escherichia coli', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341428, 'Alogliptin', 'Atazanavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341429, 'Alogliptin', 'Benazepril', 'Moderate', 'Limited clinical data suggest that dipeptidyl peptidase IV (DPP IV) inhibitors, e.g., gliptins, have been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema, such as angiotensin converting enzyme (ACE) inhibitors may theoretically increase the risk.', 'DDInter', 1767317475, 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors. Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing. Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with inhibitors, particularly in patients with advanced age and/or renal impairment and during the first month of treatment. Dosage adjustment may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.', 'Synergism', 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341430, 'Alogliptin', 'Bendroflumethiazide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341431, 'Alogliptin', 'Benzphetamine', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341432, 'Alogliptin', 'Benzthiazide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341433, 'Alogliptin', 'Betamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341434, 'Alogliptin', 'Betamethasone (topical)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341435, 'Alogliptin', 'Bexarotene', 'Major', 'Coadministration with other drugs that are known to increase triglyceride levels or cause pancreatic toxicity may potentiate the risk of pancreatitis associated with the use of bexarotene.', 'DDInter', 1767317475, 'Caution is advised when bexarotene is given in combination with other medications that are known to increase triglyceride levels or associated with pancreatic toxicity. Other risk factors such as a history of pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, or biliary tract disease should also be considered when weighing benefits versus risks of bexarotene therapy. All patients treated with bexarotene should have fasting blood lipids measured before initiating therapy, weekly during therapy until the lipid response to bexarotene is established (usually within two to four weeks), and at 8-week intervals thereafter.', 'Synergism', 'Caution is advised when bexarotene is given in combination with other medications that are known to increase triglyceride levels or associated with pancreatic toxicity.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341436, 'Alogliptin', 'Bortezomib', 'Moderate', 'Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.', 'Others', 'Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341437, 'Alogliptin', 'Brentuximab vedotin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341438, 'Alogliptin', 'Brexpiprazole', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341439, 'Alogliptin', 'Brigatinib', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341440, 'Alogliptin', 'Bumetanide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341441, 'Alogliptin', 'Calaspargase pegol', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341442, 'Alogliptin', 'Captopril', 'Moderate', 'Limited clinical data suggest that dipeptidyl peptidase IV (DPP IV) inhibitors, e.g., gliptins, have been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema, such as angiotensin converting enzyme (ACE) inhibitors may theoretically increase the risk.', 'DDInter', 1767317475, 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors. Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing. Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with inhibitors, particularly in patients with advanced age and/or renal impairment and during the first month of treatment. Dosage adjustment may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.', 'Synergism', 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341443, 'Alogliptin', 'Cariprazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341444, 'Alogliptin', 'Ceritinib', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341445, 'Alogliptin', 'Chlorothiazide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341446, 'Alogliptin', 'Chlorpromazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341447, 'Alogliptin', 'Chlorpropamide', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341448, 'Alogliptin', 'Chlorthalidone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341449, 'Alogliptin', 'Chromic chloride', 'Moderate', 'Pharmacologic dosages of chromium (200 mcg/day or more for adults) may help improve diabetic control and reduce the requirements for insulin and other antidiabetic agents. Chromium appears to play a role in normal insulin function and glucose utilization.', 'DDInter', 1767317475, 'Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents. Patients should be monitored for changes in diabetic medication requirements.', 'Synergism', 'Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341450, 'Alogliptin', 'Chromium picolinate', 'Moderate', 'Pharmacologic dosages of chromium (200 mcg/day or more for adults) may help improve diabetic control and reduce the requirements for insulin and other antidiabetic agents. Chromium appears to play a role in normal insulin function and glucose utilization.', 'DDInter', 1767317475, 'Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents. Patients should be monitored for changes in diabetic medication requirements.', 'Synergism', 'Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341451, 'Alogliptin', 'Cinoxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341452, 'Alogliptin', 'Ciprofloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341453, 'Alogliptin', 'Clarithromycin', 'Moderate', 'Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.', 'DDInter', 1767317475, 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Metabolism', 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341454, 'Alogliptin', 'Clobetasol (topical)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341455, 'Alogliptin', 'Clocortolone (topical)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341456, 'Alogliptin', 'Clozapine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341457, 'Alogliptin', 'Conjugated estrogens', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341458, 'Alogliptin', 'Conjugated estrogens (topical)', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341459, 'Alogliptin', 'Copanlisib', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341460, 'Alogliptin', 'Corticotropin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341461, 'Alogliptin', 'Tetracosactide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341462, 'Alogliptin', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 1767317475, 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341463, 'Alogliptin', 'Danazol', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341464, 'Alogliptin', 'Darunavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341465, 'Alogliptin', 'Deflazacort', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341466, 'Alogliptin', 'Delafloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341467, 'Alogliptin', 'Desonide (topical)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341468, 'Alogliptin', 'Desoximetasone (topical)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341469, 'Dexamethasone', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341470, 'Alogliptin', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341471, 'Dexamethasone (topical)', 'Alogliptin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341472, 'Alogliptin', 'Dexfenfluramine', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341473, 'Diazoxide', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341474, 'Diclofenamide', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341475, 'Dienestrol (topical)', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341476, 'Diethylpropion', 'Alogliptin', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341477, 'Diethylstilbestrol', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341478, 'Diflorasone (topical)', 'Alogliptin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341479, 'Dobutamine', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341480, 'Dopamine', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341481, 'Drospirenone', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341482, 'Enalapril', 'Alogliptin', 'Moderate', 'Limited clinical data suggest that dipeptidyl peptidase IV (DPP IV) inhibitors, e.g., gliptins, have been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema, such as angiotensin converting enzyme (ACE) inhibitors may theoretically increase the risk.', 'DDInter', 1767317475, 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors. Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing. Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with inhibitors, particularly in patients with advanced age and/or renal impairment and during the first month of treatment. Dosage adjustment may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.', 'Synergism', 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341483, 'Enfortumab vedotin', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341484, 'Enoxacin', 'Alogliptin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341485, 'Ephedrine', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341486, 'Esterified estrogens', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341487, 'Estradiol', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341488, 'Estradiol (topical)', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341489, 'Estramustine', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341490, 'Estrone', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341491, 'Estrone sulfate', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341492, 'Estrone sulfate (topical)', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341493, 'Etacrynic acid', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341494, 'Etonogestrel', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341495, 'Everolimus', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341496, 'Fenfluramine', 'Alogliptin', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341497, 'Fludrocortisone', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341498, 'Fluocinonide (topical)', 'Alogliptin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341499, 'Fluphenazine', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341500, 'Flurandrenolide (topical)', 'Alogliptin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341501, 'Fluticasone (topical)', 'Alogliptin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341502, 'Gatifloxacin', 'Alogliptin', 'Major', 'Gatifloxacin may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of various quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.', 'DDInter', 1767317475, 'The use of gatifloxacin is contraindicated in patients with diabetes mellitus. Other quinolones may be safer alternatives in such patients, although all quinolones should be used with caution. Blood glucose should be closely monitored whenever quinolones are prescribed to patients receiving insulin or other antidiabetic agents, especially if they are elderly or have renal impairment. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', 'Antagonism', 'The use of gatifloxacin is contraindicated in patients with diabetes mellitus.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341503, 'Ginseng', 'Alogliptin', 'Moderate', 'Coadministration of ginseng with antidiabetic drugs may potentiate the risk of hypoglycemia. Clinical data are conflicting. Some small studies have reported that ginseng reduced the blood levels of glucose and/or glycosylated hemoglobin (HbA1C) in diabetic patients, whereas others have not. Furthermore, the lack of standardized preparations of ginseng may limit the generalization of study results.', 'DDInter', 1767317475, 'Until more information is available, blood glucose should be monitored if antidiabetic agents are used concomitantly with ginseng. Patients should be advised on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia), how to treat it, and to contact their doctor if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.', 'Synergism', 'Until more information is available, blood glucose should be monitored if antidiabetic agents are used concomitantly with ginseng.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341504, 'Glimepiride', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341505, 'Glipizide', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341506, 'Glyburide', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341507, 'Goserelin', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341508, 'Grepafloxacin', 'Alogliptin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341509, 'Halcinonide (topical)', 'Alogliptin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341510, 'Alogliptin', 'Ulobetasol (topical)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341511, 'Histrelin', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341512, 'Hydroflumethiazide', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341513, 'Iloperidone', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341514, 'Indacaterol', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341515, 'Indapamide', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341516, 'Indinavir', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341517, 'Insulin human', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341518, 'Insulin aspart (aspart)', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341519, 'Insulin aspart (aspart protamine)', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341520, 'Insulin degludec', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341521, 'Insulin detemir', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341522, 'Insulin glargine', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341523, 'Insulin glulisine', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341524, 'Insulin human (inhalation, rapid acting)', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341525, 'Insulin human (isophane)', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341526, 'Insulin lispro', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341527, 'Insulin lispro (protamine)', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341528, 'Insulin human (regular)', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341529, 'Insulin human (zinc)', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341530, 'Insulin human (zinc extended)', 'Alogliptin', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341531, 'Isoniazid', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341532, 'Isoprenaline', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341533, 'Alogliptin', 'Lanreotide', 'Moderate', 'Somatostatin analogs may alter the therapeutic response to insulin and other antidiabetic agents. Somatostatin analogs can induce hyperglycemia and, less frequently, hypoglycemia, by inhibiting the secretion of various counter-regulatory hormones involved in glucose homeostasis (i.e., glucagon, insulin, growth hormone, incretin hormones).', 'DDInter', 1767317475, 'Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes. Glycemic status including fasting plasma glucose and/or hemoglobin A1c should be assessed prior to initiation of therapy and periodically during therapy in accordance with manufacturer''s product labeling, and the antidiabetic treatment adjusted as necessary.', 'Antagonism', 'Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341534, 'Alogliptin', 'Leuprolide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341535, 'Alogliptin', 'Levofloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341536, 'Alogliptin', 'Levonorgestrel', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341537, 'Alogliptin', 'Levothyroxine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341538, 'Alogliptin', 'Liothyronine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341539, 'Alogliptin', 'Liotrix', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341540, 'Alogliptin', 'Lisinopril', 'Moderate', 'Limited clinical data suggest that dipeptidyl peptidase IV (DPP IV) inhibitors, e.g., gliptins, have been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema, such as angiotensin converting enzyme (ACE) inhibitors may theoretically increase the risk.', 'DDInter', 1767317475, 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors. Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing. Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with inhibitors, particularly in patients with advanced age and/or renal impairment and during the first month of treatment. Dosage adjustment may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.', 'Synergism', 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341541, 'Alogliptin', 'Lithium carbonate', 'Moderate', 'Lithium may interfere with the therapeutic effects of insulin and other antidiabetic agents.', 'DDInter', 1767317475, 'Blood glucose should be monitored more closely following initiation or discontinuation of lithium in patients receiving insulin or other antidiabetic agents. If hypo- or hyperglycemia occur during lithium therapy, patients should initiate appropriate remedial therapy immediately and contact their physician. Dosage adjustments may be required if an interaction is suspected.', 'Others', 'Blood glucose should be monitored more closely following initiation or discontinuation of lithium in patients receiving insulin or other antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341542, 'Alogliptin', 'Lomefloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341543, 'Alogliptin', 'Lorcaserin', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341544, 'Alogliptin', 'Lumateperone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341545, 'Alogliptin', 'Lurasidone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341546, 'Alogliptin', 'Mazindol', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341547, 'Alogliptin', 'Medroxyprogesterone acetate', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341548, 'Alogliptin', 'Megestrol acetate', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341549, 'Alogliptin', 'Mephentermine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341550, 'Alogliptin', 'Mesoridazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341551, 'Alogliptin', 'Orciprenaline', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341552, 'Alogliptin', 'Metaraminol', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341553, 'Alogliptin', 'Metamfetamine', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341554, 'Alogliptin', 'Methazolamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341555, 'Alogliptin', 'Methdilazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341556, 'Alogliptin', 'Methotrimeprazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341557, 'Alogliptin', 'Methoxamine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341558, 'Alogliptin', 'Methylprednisolone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341559, 'Alogliptin', 'Methylprednisolone (topical)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341560, 'Alogliptin', 'Metolazone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341561, 'Alogliptin', 'Midostaurin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341562, 'Alogliptin', 'Moexipril', 'Moderate', 'Limited clinical data suggest that dipeptidyl peptidase IV (DPP IV) inhibitors, e.g., gliptins, have been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema, such as angiotensin converting enzyme (ACE) inhibitors may theoretically increase the risk.', 'DDInter', 1767317475, 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors. Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing. Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with inhibitors, particularly in patients with advanced age and/or renal impairment and during the first month of treatment. Dosage adjustment may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.', 'Synergism', 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341563, 'Alogliptin', 'Moxifloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341564, 'Alogliptin', 'Nalidixic acid', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341565, 'Alogliptin', 'Nateglinide', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341566, 'Alogliptin', 'Nelfinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341567, 'Alogliptin', 'Niacin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341568, 'Alogliptin', 'Nicotinamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341569, 'Alogliptin', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341570, 'Alogliptin', 'Norethisterone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341571, 'Alogliptin', 'Norfloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341572, 'Alogliptin', 'Norgestrel', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341573, 'Alogliptin', 'Octreotide', 'Moderate', 'Somatostatin analogs may alter the therapeutic response to insulin and other antidiabetic agents. Somatostatin analogs can induce hyperglycemia and, less frequently, hypoglycemia, by inhibiting the secretion of various counter-regulatory hormones involved in glucose homeostasis (i.e., glucagon, insulin, growth hormone, incretin hormones).', 'DDInter', 1767317475, 'Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes. Glycemic status including fasting plasma glucose and/or hemoglobin A1c should be assessed prior to initiation of therapy and periodically during therapy in accordance with manufacturer''s product labeling, and the antidiabetic treatment adjusted as necessary.', 'Antagonism', 'Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341574, 'Alogliptin', 'Ofloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341575, 'Alogliptin', 'Olanzapine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341576, 'Alogliptin', 'Omacetaxine mepesuccinate', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341577, 'Alogliptin', 'Orlistat', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341578, 'Alogliptin', 'Paliperidone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341579, 'Alogliptin', 'Pasireotide', 'Moderate', 'Somatostatin analogs may alter the therapeutic response to insulin and other antidiabetic agents. Somatostatin analogs can induce hyperglycemia and, less frequently, hypoglycemia, by inhibiting the secretion of various counter-regulatory hormones involved in glucose homeostasis (i.e., glucagon, insulin, growth hormone, incretin hormones).', 'DDInter', 1767317475, 'Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes. Glycemic status including fasting plasma glucose and/or hemoglobin A1c should be assessed prior to initiation of therapy and periodically during therapy in accordance with manufacturer''s product labeling, and the antidiabetic treatment adjusted as necessary.', 'Antagonism', 'Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341580, 'Alogliptin', 'Pegaspargase', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341581, 'Alogliptin', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341582, 'Alogliptin', 'Pentamidine', 'Moderate', 'Pentamidine may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of pentamidine has been associated with disturbances in blood glucose homeostasis due to direct toxic effects on beta cells of the pancreas. Hypoglycemia, which may be severe and/or prolonged, as well as hyperglycemia and insulin-dependent diabetes mellitus, the latter of which may be irreversible, have been reported.', 'DDInter', 1767317475, 'Blood glucose should be monitored closely during and after pentamidine therapy in patients receiving insulin or other antidiabetic agents, especially if they are elderly or have renal impairment. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during pentamidine therapy, patients should initiate appropriate remedial therapy immediately and contact their physician. Dosage adjustments may be required if an interaction is suspected.', 'Antagonism', 'Blood glucose should be monitored closely during and after pentamidine therapy in patients receiving insulin or other antidiabetic agents, especially if they are elderly or have renal impairment.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341583, 'Alogliptin', 'Perindopril', 'Moderate', 'Limited clinical data suggest that dipeptidyl peptidase IV (DPP IV) inhibitors, e.g., gliptins, have been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema, such as angiotensin converting enzyme (ACE) inhibitors may theoretically increase the risk.', 'DDInter', 1767317475, 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors. Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing. Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with inhibitors, particularly in patients with advanced age and/or renal impairment and during the first month of treatment. Dosage adjustment may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.', 'Synergism', 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341584, 'Alogliptin', 'Perphenazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341585, 'Alogliptin', 'Phendimetrazine', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341586, 'Alogliptin', 'Phentermine', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341587, 'Alogliptin', 'Phenylpropanolamine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341588, 'Alogliptin', 'Phenytoin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341589, 'Alogliptin', 'Polythiazide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341590, 'Alogliptin', 'Prednicarbate (topical)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341591, 'Alogliptin', 'Prednisolone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341592, 'Alogliptin', 'Prednisone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341593, 'Alogliptin', 'Prochlorperazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341594, 'Alogliptin', 'Progesterone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341595, 'Alogliptin', 'Progesterone (topical)', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341596, 'Alogliptin', 'Promazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341597, 'Alogliptin', 'Promethazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341598, 'Alogliptin', 'Propiomazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341599, 'Alogliptin', 'Quetiapine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341600, 'Alogliptin', 'Quinestrol', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341601, 'Alogliptin', 'Ramipril', 'Moderate', 'Limited clinical data suggest that dipeptidyl peptidase IV (DPP IV) inhibitors, e.g., gliptins, have been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema, such as angiotensin converting enzyme (ACE) inhibitors may theoretically increase the risk.', 'DDInter', 1767317475, 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors. Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing. Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with inhibitors, particularly in patients with advanced age and/or renal impairment and during the first month of treatment. Dosage adjustment may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.', 'Synergism', 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341602, 'Alogliptin', 'Repaglinide', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341603, 'Alogliptin', 'Risperidone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341604, 'Alogliptin', 'Ritodrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341605, 'Alogliptin', 'Ritonavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341606, 'Alogliptin', 'Salmeterol', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341607, 'Alogliptin', 'Saquinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341608, 'Alogliptin', 'Sermorelin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341609, 'Alogliptin', 'Sibutramine', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341610, 'Alogliptin', 'Sirolimus', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341611, 'Alogliptin', 'Somapacitan', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341612, 'Alogliptin', 'Somatrem', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341613, 'Alogliptin', 'Somatotropin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341614, 'Alogliptin', 'Sparfloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341615, 'Alogliptin', 'Sucralfate', 'Moderate', 'Due to the carbohydrate content in the excipients, sucralfate oral suspension (but not the tablet) may interfere with the therapeutic effects of insulin and other antidiabetic agents.', 'DDInter', 1767317475, 'Caution is advised when sucralfate oral suspension is prescribed to patients with diabetes. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of sucralfate treatment, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Others', 'Caution is advised when sucralfate oral suspension is prescribed to patients with diabetes.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341616, 'Alogliptin', 'Tacrolimus', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341617, 'Alogliptin', 'Tagraxofusp', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341618, 'Alogliptin', 'Temsirolimus', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341619, 'Alogliptin', 'Teprotumumab', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341620, 'Alogliptin', 'Terbutaline', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341621, 'Alogliptin', 'Tesamorelin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341622, 'Alogliptin', 'Thiethylperazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341623, 'Alogliptin', 'Thioridazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341624, 'Alogliptin', 'Thyroid, porcine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341625, 'Alogliptin', 'Thyrotropin alfa', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341626, 'Alogliptin', 'Tipranavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341627, 'Alogliptin', 'Tolazamide', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341628, 'Alogliptin', 'Tolbutamide', 'Moderate', 'Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341629, 'Alogliptin', 'Torasemide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341630, 'Alogliptin', 'Trandolapril', 'Moderate', 'Limited clinical data suggest that dipeptidyl peptidase IV (DPP IV) inhibitors, e.g., gliptins, have been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema, such as angiotensin converting enzyme (ACE) inhibitors may theoretically increase the risk.', 'DDInter', 1767317475, 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors. Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing. Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with inhibitors, particularly in patients with advanced age and/or renal impairment and during the first month of treatment. Dosage adjustment may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.', 'Synergism', 'Clinicians and patients should be aware of the potential for increased risk of angioedema when inhibitors are prescribed with ACE inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341631, 'Alogliptin', 'Triamcinolone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341632, 'Alogliptin', 'Triamcinolone (ophthalmic)', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341633, 'Alogliptin', 'Triamcinolone (topical)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341634, 'Alogliptin', 'Trichlormethiazide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341635, 'Alogliptin', 'Trifluoperazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341636, 'Alogliptin', 'Triflupromazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341637, 'Alogliptin', 'Alimemazine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341638, 'Alogliptin', 'Triptorelin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341639, 'Alogliptin', 'Trovafloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341640, 'Alogliptin', 'Turmeric', 'Moderate', 'Coadministration of turmeric with antidiabetic drugs might potentiate the risk of hypoglycemia.', 'DDInter', 1767317475, 'Blood glucose should be monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.', 'Synergism', 'Blood glucose should be monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341641, 'Alogliptin', 'Vorinostat', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341642, 'Alogliptin', 'Ziprasidone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341643, 'Acetohexamide', 'Metformin', 'Moderate', 'Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used with metformin.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341644, 'Aloe Vera Leaf', 'Metformin', 'Moderate', 'Concomitant use of oral products containing aloe vera gel may potentiate the hypoglycemic effect of insulin and other antidiabetic agents.', 'DDInter', 1767317475, 'Until more data are available, caution is advised when aloe vera is administered orally to patients receiving insulin or other antidiabetic agents due to the potential for increased risk of hypoglycemia. Patients should be monitored for changes in diabetic medication requirements.', 'Synergism', 'Until more data are available, caution is advised when aloe vera is administered orally to patients receiving insulin or other antidiabetic agents due to the potential for increased risk of hypoglycemia.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341645, 'Alpelisib', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341646, 'Metformin', 'Lipoic acid', 'Minor', 'Theoretically, alpha-lipoic acid may potentiate the hypoglycemic effect of insulin and oral antidiabetic agents. Alpha-lipoic acid has been shown to improve insulin sensitivity and glucose utilization in lean and obese patients with type II diabetes.', 'DDInter', 1767317475, '-', 'Synergism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341647, 'Amcinonide', 'Metformin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341648, 'Amiloride', 'Metformin', 'Moderate', 'Amiloride is a cationic drug and theoretically could decrease the excretion of metformin by competing for renal tubular transport. Increased metformin levels may increase the risk of lactic acidosis.', 'DDInter', 1767317475, 'Particularly slow and cautious titration of metformin dosage is recommended if these drugs must be used together. The maximal dose of metformin should also be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.', 'Excretion', 'Particularly slow and cautious titration of metformin dosage is recommended if these drugs must be used together.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341649, 'Amprenavir', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341650, 'Anisindione', 'Metformin', 'Moderate', 'Coadministration with metformin may decrease the anticoagulant effects of vitamin K antagonists (VKAs). The mechanism has not been delineated, but it may involve metformin-mediated increase in the elimination rate of VKAs. In addition, concomitant use of VKAs with metformin may increase the risk of severe hypoglycemia. The clinical significance of this interaction is unknown.', 'DDInter', 1767317475, 'Until more information is available, patients receiving VKAs with metformin should be closely monitored during concomitant therapy. The INR or prothrombin time should be checked frequently and the VKA dosage adjusted accordingly, particularly following initiation, change of dosage, or discontinuation of metformin therapy. In addition, patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs.', 'Metabolism', 'Until more information is available, patients receiving VKAs with metformin should be closely monitored during concomitant therapy.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341651, 'Aripiprazole', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341652, 'Asenapine', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341653, 'Asparaginase Erwinia chrysanthemi', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341654, 'Atazanavir', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341655, 'Bendroflumethiazide', 'Metformin', 'Moderate', 'Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341656, 'Benzphetamine', 'Metformin', 'Moderate', 'Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Synergism', 'Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341657, 'Betamethasone', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341658, 'Bortezomib', 'Metformin', 'Moderate', 'Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.', 'Others', 'Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341659, 'Brentuximab vedotin', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341660, 'Brexpiprazole', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341661, 'Brigatinib', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341662, 'Bromfenac', 'Metformin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.', 'DDInter', 1767317475, 'Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', 'Others', 'Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341663, 'Bumetanide', 'Metformin', 'Moderate', 'Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341664, 'Calaspargase pegol', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341665, 'Capmatinib', 'Metformin', 'Moderate', 'Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of multidrug and toxin extrusion 1 and 2K (MATE1 and MATE2K) proteins, such as methylnaltrexone and tipiracil. The proposed mechanism is decreased clearance due to capmatinib-mediated inhibition of MATE1 and/or MATE2K.', 'DDInter', 1767317475, 'Coadministration of capmatinib with drugs that are substrates of MATE1 and/or MATE2K should generally be avoided. However, if concomitant use is unavoidable, caution is advised, particularly with drugs that have a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever capmatinib is added to or withdrawn from therapy with these drugs, and the dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Coadministration of capmatinib with drugs that are substrates of MATE1 and/or MATE2K should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341666, 'Captopril', 'Metformin', 'Moderate', 'Limited data suggest that ACE inhibitors may potentiate the hypoglycemic effects of oral antidiabetic drugs, including metformin. The mechanism is unknown. Symptomatic and sometimes severe hypoglycemia has occurred.', 'DDInter', 1767317475, 'Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with metformin, particularly in patients with advanced age and/or renal impairment. Dosage adjustments may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs. Patients should be observed for loss of glycemic control when ACE inhibitors are withdrawn.', 'Others', 'Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with metformin, particularly in patients with advanced age and/or renal impairment.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341667, 'Cariprazine', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341668, 'Celecoxib', 'Metformin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.', 'DDInter', 1767317475, 'Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', 'Others', 'Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341669, 'Cephalexin', 'Metformin', 'Moderate', 'The concomitant administration of cephalexin may increase plasma concentrations and adverse effects of metformin. The mechanism is competitive inhibition of active renal tubular secretion.', 'DDInter', 1767317475, 'Patients receiving this combination should be monitored for altered efficacy and safety of metformin. Metformin dose adjustments may be required.', 'Excretion', 'Patients receiving this combination should be monitored for altered efficacy and safety of metformin.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341670, 'Ceritinib', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341671, 'Chlorothiazide', 'Metformin', 'Moderate', 'Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341672, 'Chlorpromazine', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341673, 'Chlorpropamide', 'Metformin', 'Moderate', 'Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.', 'DDInter', 1767317475, 'A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.', 'Synergism', 'A lower dosage of the insulin secretagogue or insulin may be required when used with metformin.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341674, 'Chlorthalidone', 'Metformin', 'Moderate', 'Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341675, 'Chromic chloride', 'Metformin', 'Moderate', 'Pharmacologic dosages of chromium (200 mcg/day or more for adults) may help improve diabetic control and reduce the requirements for insulin and other antidiabetic agents. Chromium appears to play a role in normal insulin function and glucose utilization.', 'DDInter', 1767317475, 'Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents. Patients should be monitored for changes in diabetic medication requirements.', 'Synergism', 'Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341676, 'Chromium picolinate', 'Metformin', 'Moderate', 'Pharmacologic dosages of chromium (200 mcg/day or more for adults) may help improve diabetic control and reduce the requirements for insulin and other antidiabetic agents. Chromium appears to play a role in normal insulin function and glucose utilization.', 'DDInter', 1767317475, 'Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents. Patients should be monitored for changes in diabetic medication requirements.', 'Synergism', 'Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341677, 'Cimetidine', 'Metformin', 'Moderate', 'Cimetidine may significantly reduce the renal tubular secretion of metformin. The mechanism may involve cimetidine inhibition of the organic cation transporter 2 (OCT2), thereby increasing metformin plasma concentration. Increased metformin levels may increase the risk of lactic acidosis.', 'DDInter', 1767317475, 'Particularly slow and cautious titration of metformin dosage is recommended if these drugs must be used together. The maximal dose of metformin should also be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as nausea, vomiting, malaise, myalgia, weakness, respiratory distress, slow or irregular heartbeat, dizziness, lightheadedness, or other unusual symptoms.', 'Excretion', 'Particularly slow and cautious titration of metformin dosage is recommended if these drugs must be used together.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341678, 'Ciprofloxacin', 'Metformin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341679, 'Clarithromycin', 'Metformin', 'Moderate', 'Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.', 'DDInter', 1767317475, 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Metabolism', 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341680, 'Clobetasol (topical)', 'Metformin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341681, 'Clocortolone (topical)', 'Metformin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'DDInter', 1767317475, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341682, 'Clozapine', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341683, 'Colesevelam', 'Metformin', 'Moderate', 'Coadministration with colesevelam may increase the plasma concentrations of metformin. The mechanism of interaction has not been described.', 'DDInter', 1767317475, 'Caution is advised if metformin is used concomitantly with colesevelam. Clinical response and tolerance to metformin should be monitored more closely following the initiation or discontinuation of colesevelam. Patients should be advised to contact their physician if they experience increased side effects of metformin such as nausea, vomiting, diarrhea, flatulence, indigestion, and asthenia. Immediate medical attention should be sought if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, somnolence, abdominal distress, respiratory distress, hyperventilation, slow or irregular heartbeat, and hypothermia.', 'Others', 'Caution is advised if metformin is used concomitantly with colesevelam.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341684, 'Conjugated estrogens (topical)', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341685, 'Copanlisib', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341686, 'Tetracosactide', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341687, 'Crizotinib', 'Metformin', 'Moderate', 'Coadministration with crizotinib may theoretically increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2B6 (e.g., bupropion), P-glycoprotein (P-gp) (e.g., dabigatran), and/or the organic cation transporters 1 and 2 (OCT1, OCT2) (e.g., metformin). The proposed mechanism, based on in vitro data, is decreased clearance due to crizotinib-mediated inhibition of CYP450 2B6, P-gp, and/or OCT1 or OCT2.', 'DDInter', 1767317475, 'Although the clinical significance is unknown, caution is advised if crizotinib is used concomitantly with drugs that are substrates of CYP450 2B6, P-gp, and/or OCT1 or OCT2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever crizotinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Although the clinical significance is unknown, caution is advised if crizotinib is used concomitantly with drugs that are substrates of CYP450 2B6, P-gp, and/or OCT1 or OCT2, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341688, 'Dabrafenib', 'Metformin', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 1767317475, 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341689, 'Daclatasvir', 'Metformin', 'Moderate', 'Coadministration with daclatasvir may increase the systemic exposure and risk of adverse effects of drugs that are substrates of the hepatic uptake transporter, organic cation transporter 1 (OCT1). The proposed mechanism is decreased clearance due to daclatasvir-mediated inhibition of OCT1. The clinical significance is unknown.', 'DDInter', 1767317475, 'Caution is advised if daclatasvir is used concomitantly with drugs that are substrates of OCT1, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever daclatasvir is added to or withdrawn from therapy with these drugs. Patients should also be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised if daclatasvir is used concomitantly with drugs that are substrates of OCT1, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341690, 'Dalfampridine', 'Metformin', 'Moderate', 'The concomitant use of dalfampridine with drugs that are inhibitors of organic cation transporter 2 (OCT2) may theoretically reduce its renal clearance. Dalfampridine is primarily eliminated through renal excretion, approximately 60% of which is via active secretion by OCT2. Elevated levels of dalfampridine may increase the risk of CNS excitation and seizures.', 'DDInter', 1767317475, 'Caution is advised when dalfampridine is used with OCT2 inhibitors. The benefit of concomitant use should be weighed against the potential risk of seizures.', 'Excretion', 'Caution is advised when dalfampridine is used with OCT2 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341691, 'Darunavir', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341692, 'Deflazacort', 'Metformin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 1767317475, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1341693, 'Delafloxacin', 'Metformin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 1767317475, 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', NULL, NULL, 'Moderate', 'pharmacodynamic');
